AKT1 and ovarian carcinoma: In the present study, we found that TPL inhibits the growth of drug-resistant ovarian cancer in vivo and in vitro, potentially by inhibiting the polarization of M2 TAMs through the PI3K/AKT/NF-κB-signaling pathway.